Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 12/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16978720 | 0.95 | LIMK1 (0.50) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25042487 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25040021 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25042466 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25041853 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25041970 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25041972 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25042485 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25041877 | 0.90 | ESR1 (0.46) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL24619537 | 0.89 | LIMK1 (0.54) | LIMK1PIK3CAPI4KAPI4KBF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260451-B2 | Method for producing aromatic compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9260451-B2 | Method for producing aromatic compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150239901-A1 | Method For Producing Aromatic Compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150239901-A1 | Method For Producing Aromatic Compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239901-A1 | Method For Producing Aromatic Compound | TYR, XDH, CYP1A1 | LIMK1 3787/4885PIK3CA 4822/4885PI4KA 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.